Second-Generation (Atypical) Antipsychotics - PsychDB

Last edited on February 25, 2021

Second-Generation (Atypical) Antipsychotics are a class of antipsychotic medications released in the early late 1990s to 2000s.

Atypical antipsychotics block the action of dopamine (DA) in D2 receptors, and also block serotonin 5-HT2 receptors.

See main article: Metabolic Syndrome

Atypical antipsychotics are associated with metabolic syndrome, and is the greatest with use of olanzapine. Risperidone and quetiapine have intermediate effects, while aripiprazole, asenapine lurasidone, and ziprasidone have lower effects (but are not weight-neutral).^[1]

See main article: Extrapyramidal Symptoms (EPS)

See main article: Neuroleptic Malignant Syndrome (NMS)

¹⁾ Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., & Van Ameringen, M. (2014). Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC psychiatry, 14(1), 1-83.